US biotech Moderna announces groundbreaking set of results from Phase III trial, positioning mRNAs as best bet for vaccine.
In yet another breakthrough in the race to find a coronavirus vaccine, US biotech Moderna announced its mRNA-1273 candidate was 94.5% effective at preventing Covid-19. This is based on interim data from a Phase III clinical trial, yet again fueling optimism that the end to the public health crisis is near. The results make Moderna the second drugmaker to exceed expectations following the announcement by Pfizer and BioNTech last week that their vaccine candidate was more than 90% effective.
The late-stage trial enrolled 30,000 participants. However, the preliminary results are based on 95 participants administered two doses 28 days apart, similarly to Pfizer's. Notably, 90 of the participants had been in the trial's placebo group, while only five received mRNA-1273, raising concerns the celebrations might be premature. Nonetheless, the results have put the spotlight on the potential of mRNAs as frontrunners to lead the world out of the crisis having also been used in the trial by Pfizer and BioNTech.